Gamida Cell extends gains as FDA approves co's blood cancer therapy

Gamida Cell

18/04/2023 10:58

** Shares of Gamida Cell Ltd  GMDA.O  extend gains to 43.7%
at $1.57 premarket - among biggest pct gainer across the U.S.
stock exchanges before the bell
    **  U.S. FDA approves Gamida's cell therapy for cutting the
risk of infection in patients undergoing treatment for blood
cancer
    ** The approval allows the co to launch its first commercial
therapy under the brand name Omisirge for patients who are 12
years or older and are undergoing stem cell transplantation
    ** Omisirge therapy is given as a single-intravenous dose
and is made using donor stem cells obtained from umbilical cord
blood
    ** The main market opportunity or the segment that this
product could help are patients who have no immediately
available donor, said Oppenheimer analyst Mark Briedenbach,
ahead of the approval
    ** As of last close, GMDA stock lost ~13% YTD
    

 (Reporting by Khushi Mandowara in Bengaluru)
 ((Khushi.Mandowara@thomsonreuters.com;))